key: cord-1044528-s9lt94p0
authors: Balachandran, Harikrishnan; Phetsouphanh, Chansavath; Agapiou, David; Adhikari, Anurag; Rodrigo, Chaturaka; Hammoud, Mohamed; Shrestha, Lok Bahadur; Keoshkerian, Elizabeth; Gupta, Money; Turville, Stuart; Christ, Daniel; King, Cecile; Sasson, Sarah C.; Bartlett, Adam; Grubor-Bauk, Branka; Rawlinson, William; Aggarwal, Anupriya; Stella, Alberto Ospina; Klemm, Vera; Mina, Michael M.; Post, Jeffrey J.; Hudson, Bernard; Gilroy, Nicky; Konecny, Pam; Ahlenstiel, Golo; Dwyer, Dominic E.; Sorrell, Tania C.; Kelleher, Anthony; Tedla, Nicodemus; Lloyd, Andrew R.; Martinello, Marianne; Bull, Rowena A.
title: Maintenance of broad neutralising antibodies and memory B cells 12 months post-infection is predicted by SARS-CoV-2 specific CD4+ T cell responses
date: 2022-01-19
journal: Cell Rep
DOI: 10.1016/j.celrep.2022.110345
sha: fe805e3573ed66774ac85a97f3154829ef4dae9a
doc_id: 1044528
cord_uid: s9lt94p0

Understanding the long-term maintenance of SARS-CoV-2 immunity is critical for predicting protection against reinfection. In an age and gender matched cohort of 24 participants, the association of disease severity and early immune responses on the maintenance of humoral immunity 12 months post-infection is examined. All severely affected participants maintain a stable subset of SARS-CoV-2 receptor-binding domain (RBD)-specific memory B cells (MBCs) and good neutralising antibody breadth against the majority of the variants of concern, including the Delta variant. Modelling these immune responses against vaccine efficacy data indicate 45-76% protection against symptomatic infection (variant dependent). Overall, these findings indicate durable humoral responses in most participants after infection, reasonable protection against reinfection, and implicate baseline antigen-specific CD4+ T cell responses as a predictor of maintenance of antibody neutralisation breadth and RBD-specific MBC levels at 12 months post-infection.

) and mild ID50 12.89 9 (range: 0 -44.8) p=0.02 and p=0.003). However, at visit 3 disease severity did not associate 10 with the neutralising activity for these variants, similar to the D614G variant. 11 Using a scoring system similar to that used for HIV (Mishra et al., 2020) , neutralisation at 12 greater than 50% at 1/40 dilution was defined as significant. For each sample, observations of 13 significant neutralisation against each of the four variants were summed and expressed as a 14 percentage score (i.e., a score of 25% or 1 out of 4 for each of the four variants neutralised at 15 50% or greater at a dilution of 1/40). A comparison of this score between time points and 16 disease severity groups revealed that more severe disease was associated with broader 17 neutralising activity at visit 1, which was then followed by a non-significant decline by visit 3. 18 For participants with mild and moderate disease, only half the variants could be neutralised at 19 a 1/40 dilution, and this remained stable over time ( Fig.1H and Supplementary fig 1D) . Overall, 20 these results indicated that despite a decline in antibody titres, antibody functions were retained in most participants through 12 months post-infection. 22 Estimating the level of protection at 12 months 1 Two studies to-date have provided numerical estimates for levels of protection from COVID 2 vaccines (Feng et al., 2021; Khoury et al., 2021) . We applied these estimates to our natural 3 immunity data to estimate the level of protection that might be expected at 12 months post-4 infection. Both studies used values that can be universally applied. The first study associated 5 the binding antibody titres (BAU/ml) with vaccine efficacy against symptomatic breakthrough 6 infections following ChAdOx1 vaccination (Feng et al., 2021) . In this analysis, 62.5% of 7 participants had binding titres above the 60% vaccine efficacy level (50 BAU/mL anti-RBD 8 IgG) indicating that a similar efficacy of protection against symptomatic disease from natural 9 immunity may be expected in the participant group reported here. Since these titres were 10 measured against the Wuhan variant RBD, the percentage of participants protected may be 11 expected to be slightly lower for the other variants (Fig.1I ).

Neutralisation is another correlate of vaccine efficacy and a recent study used the reported 13 convalescent titres as an internal standard to enable a comparison between vaccine studies 14 (Khoury et al., 2021) . Following this approach, the 12-month titres for each variant were 15 standardised against the neutralisation titre determined for the D614G variant at visit 1. Based 16 on this observation, the findings predict that 76.5% (95% CI: 72.7-80.3), 68.0% (95% CI: 63.0-17 73.2), 61.4% (95% CI: 55.0-67.7) and 45.8% (95% CI: 36.9-54.7) of the participants in the 18 present study would have a 50% protective efficacy against symptomatic infection with the 19 Alpha, D614G, Delta and Beta variants respectively (Fig.1J) . 20 Severe disease was associated with maintenance of RBD memory B cells at 12 months 21 Longitudinal SARS-CoV-2 specific memory B cell responses (RBD-specific MBCs) were =0.0214). No significant change from visit 2 to visit 3 (V3: 344 (range: 0 -2979)) was observed 8 (Fig 2A) . Of the 20 participants who had detectable responses at visit 1, 16 (80%) still had 9 detectable responses at visit 3. Interestingly, two participants who did not have responses above 10 the threshold of detection at visit 1, did have just above detection threshold responses at visit 11 3, while a third participant who did not have detectable responses at visit 1 mounted a well 12 above threshold response at visit 3. This participant was not a vaccine recipient and since the 13 study has been conducted in a low prevalence setting, reinfection was highly unlikely. In four 14 participants, despite being recorded at high frequencies at visit 1, the MBC responses dropped 15 below the detection threshold at visit 3. Overall, class switched classical memory (CD27+ 16 IgG+) B cells specific to RBD were identified in 19 of the 24 participants (79%) 12 months 17 post infection ( Fig 2B) .

When stratified by disease severity, individual RBD-specific MBC trajectories were quite 19 varied, particularly between visits 2 and 3 ( Fig 2B and Supplementary fig 1A) . At visit 1, 100% 20 (7/7) of participants in the severely ill group, 88% (7/8) participants in the moderately ill group 21 and 67% (6/9) in the mildly ill group mounted a class switched RBD-specific classical MBC 22 response. At visit 2, 100% of the severe (7/7) and the moderately ill groups (8/8) and 67% (6/9) 23 in the mildly ill group maintained the response. At visit 3, 100% (7/7) of the severe, 75% (6/8) 24 of the moderate, and 67% (6/9) in the mildly ill group had retained detectable MBC responses.

In the mildly and moderately ill group, two participants from each, despite maintaining an 1 above-threshold response for the first two visits, lost this response at visit 3. Conversely two 2 participants in the mildly ill group who did not have detectable responses at visit 1 had low but 3 detectable responses at visit 3.

The severely ill group had higher levels of RBD-specific CD27+ IgG+ MBCs at 12 months 2008). As expected, a significant decline in the AM subset was observed from visit 1 to visit 14 3, while the RM population showed a significant expansion from visit 1 to visit 2. The TLM 15 subset decreased significantly from visit 1 to visit 2, followed by a significant increase from 16 visit 2 to visit 3. There were no significant changes in the IM subset over time ( Fig 2D) . 17 Examining the various subsets as a percentage of the total RBD-specific IgG+ MBCs at each 18 visit across the different disease severity groups revealed significant enrichment of the TLM 19 subset in the severely ill group compared to the mild and moderate disease group at visit 1 20 (mild: 0% (range: 0% -8%), moderate: 0% (range: 0% -8%), severe: 3% (range: 0% -11%) , 21 p= 0.0253 and p=0.0441) (Fig 2E) .

1 breadth and memory B cell magnitude at 12 months after infection 2 As maintenance of broadly neutralising antibodies in the serum and RBD-specific memory B 3 cells are key features of long-lived protective immunity, the features of the early immune 4 response after infection resolution (visit 1) were examined to determine if they were predictive 5 of a sustained humoral immune response at 12 months (visit 3). As CD4+ T cells have a key 6 role in generation of antibody and B cell responses, SARS-CoV-2 specific CD4+ T cell 7 responses were measured at visit 1 with an activation induced marker (AIM) assay using 8 peptide pools against the: SARS-CoV-2 Nucleoprotein (NP), Spike excluding RBD (SN), RBD 9 only (SR), and influenza (Flu, as a control). Exhaustion markers Tim-3+ and PD-1+ were also 10 determined ex vivo on total CD4+ T cell subsets. Antigen-specific OX40+ CD4+ T cells 11 (CD134+ CD25+) cells were detected in 100% of participants ( Fig 3A) and the frequency of The different CD4+ T cell response measurements at visit 1 correlated positively between most 11 of the different CD4+ T cell subsets at visit 1. One notable exception was that the ex vivo 12 CXCR5+ Tim-3+ PD-1+ exhausted CD4+ T cell subset inversely correlated with most antigen- p=0.02), SR cTfh Th17 (r=0.43 p=0.04) and SR cTfh Th1/Th17 (r=0.55 p=0.006) (Fig 3E) . 20 Interestingly, the breadth of neutralisation at visit 3 did not correlate with the NP cTfh antigen. MBCs are a source of rapid production of high titre antibodies upon reinfection. As a 7 dichotomy in maintenance of the MBC responses was observed over time in the cohort, the 8 participants were divided based on whether the magnitude of the MBC responses were 9 maintained or declined over the 12 months (Supplementary figure 2D) (with decline defined 10 as a decrease in the response that was two-fold greater than the coefficient of variation of the 11 assay). Based on this criterion, 10 out 24 participants (41.67%) were categorised into the 12 'declines' category. In order to investigate if immune parameters at visit 1 were associated with 13 maintenance versus decline of the RBD+ IgG+ MBC response at visit 3, a principal component 14 analysis (PCA) was performed on the visit 1 immunological variables and revealed clustering 15 based on either maintained or declined MBC responses ( Fig 3F) . Interestingly, no clustering 16 based on the disease severity was observed. A loading plot identified several variables that 17 were positively associated with the maintenance of RBD+ IgG+ MBCs, which were then 18 confirmed with logistic regression. These included CD4+ OX40+ T cells, cTfh and Th2 cells.

In general, the CD25+ OX40+ CD4+ T cell frequencies were higher against all three antigens 20 in the group that maintained their MBC responses and were significant for the SN (p=0.0305), 21 SR (p=0.0221) and NP antigen (p=0.0293) ( Fig 3G) . Within the SARS-CoV-2 reactive subset (OX40+), the group that maintained their responses generally had a lower proportion of cTfh 23 cells, with this trend being consistent across all three antigen groups though not reaching 24 statistical significance ( Fig 3H) . However, within the cTfh subset the group that maintained responses were enriched for the Th2 subset, this trend was observed for all SARS-CoV-2 1 antigens, but not Flu antigen, and was significant for the RBD (SR) antigen (p=0.0221) (Fig   2   3I ).

In summary, these data suggest that maintenance of high titre and broad neutralising antibodies 4 was associated with strong cTfh responses, in particular the Th1/Th17 subset (CXCR3+ 5 CCR6+), whereas maintenance of memory B cells was associated with a strong general Spike 6 and RBD specific CD4+ T cell response. It is becoming increasingly evident that achieving herd immunity against SARS-CoV-2 9 infection through vaccination alone is hard but should a durable natural immune response to 10 infection be generated, this could become a key contributor to this goal. Further, maintenance 11 of a high-quality protective response is becoming increasingly important with ongoing 12 development and transmission of new variants of concern (VOCs). In this study, we report 13 several findings, some of which confirm key findings reported by other groups regarding the 14 duration of the different components of the humoral immune response during convalescence 15 after SARS-CoV-2 infection. At 12 months, despite declining anti-RBD IgG antibody titres, 16 the majority of participants maintained ADCP and neutralising activity. The retention of 17 neutralising breadth against most VOCs, including the currently circulating Delta variant, is 18 especially encouraging. RBD-specific MBC responses were also maintained in just over half 19 of the participants. In this study we found that the frequency of the antigen specific CD4+ T 20 cell subsets at baseline predicted the maintenance of the MBC subsets at 12 months. 21 There was a sharp decline in the anti-RBD antibody titres during the initial convalescent phase 22 followed by stabilisation out to 12 months consistent with previous reports (Li et al., 2021; 23 Turner et al., 2021). As reported by others in early infection (Chen et al., 2020) , the antibody levels in our study remained significantly higher in participants with severe disease when 1 compared to those with mild disease even out to 12 months post-infection in our age and gender 2 matched sub-cohorts. This is an important finding as in most studies the severe disease group 3 is biased towards an older population. This finding in our cohort therefore suggests that 4 antibody level is specifically associated with disease severity. During SARS-CoV-2 infection, 

We also observed that most of the convalescent sera had detectable neutralising activity against 16 the VOCs, with higher neutralising activity against the D614G and Alpha variants than the At this stage there is no study that has directly correlated antibody titres at the time of exposure 1 and protection. Among people who received the ChAdOx1 vaccine, antibodies were measured 2 at approximately 28 days after the second dose and then correlated with the risk of symptomatic 3 infection in participants in the subsequent 4 -6 months (Feng et al., 2021) . As antibody titres 4 are likely to decline after immunisation, the titres at the time of infection were likely to have 5 been lower than those present when measured at the peak of the response. In our study, antibody 6 titres at 12 months were similar to those associated with a vaccine efficacy of 60% against mild 7 disease, therefore we believe our estimated correlate of protection is quite conservative, and 8 our cohort may have a protective efficacy against symptomatic disease that is greater than 9 60%. Our analysis of the neutralising titres against the different variants predicts that this level 10 of protection will be impacted by the variant of the infecting strain, with a low level of 11 protection predicted for the known immune escape variant, Beta. Encouragingly the predicted 12 level of protection against symptomatic disease from the currently circulating Delta virus was 13 higher at approximately 60%. In concordance with new modelling published recently, we 14 speculate that boosting our cohort with one immunisation dose will lead to increased protection 15 (Cromer et al., 2021). 16 The neutralising breadth of the antibodies at 12 months in our cohort generally correlated with 17 baseline Spike and RBD specific cTfh subsets. Similar to other reports in early convalescence longitudinally is important. One additional difference in our study in comparison to two other 15 similar studies is that we had a larger representation of severe disease (29% vs 10% -12%) 16 (Juno et al., 2020; Wang et al., 2021) and this group was age matched, thereby minimising age 17 associated biases in the immunological analysis allowing a more focused look at the long-term 18 immunological impact of severe disease.

The rationale behind reporting the RBD-specific MBCs instead of the more commonly reported 20 Spike-specific MBCs, was that the latter tend to be more cross-reactive against other common 21 Coronaviruses. However, a strong correlation between the RBD-specific MBC numbers and 22 the Spike-specific MBC numbers was observed at visit 3 (Supplementary fig 2E) . The initial 23 increase in MBC levels from visit 1 to visit 2 was followed by a relative stabilisation at 12 24 months, in line with another analysis (Wang et al., 2021) . As the second line of defence, the maintenance of the magnitude of the MBC repertoire is critical for mounting an anamnestic 1 response in the event of reinfection.

The magnitude of the RBD-specific MBC responses at each visit correlated with the anti-RBD 3 IgG antibody levels at that visit (Supplementary fig 2F) . The initial anti-RBD IgG antibody 4 levels also correlated with the RBD-specific MBC levels at 12 months (Supplementary fig 2G) .

The severity of the disease had a significant impact on the magnitude of the MBC subset with 6 those recovering from severe COVID having higher levels of RBD-specific MBCs than the 7 mild or moderate disease groups, indicating that a small proportion of these two groups may Overall, the data from this study support the proposed model, that B cells that receive limited help from Tfh cells will differentiate into memory B cells, whereas those with a higher level of 1 help will re-enter the GC reaction for further maturation and potential differentiation into 2 antibody secreting cells. 

The relatively small sample size limits the scope of the findings reported in this study.

However, since our aim was to understand the kinetics of the durability of SARS-CoV-2-specific immune responses and identify the predictors of durable responses, the study focused 1 on an age-and gender-matched cohort stratified by disease severity, purposively selected from 2 a larger cohort. This design ensured that we were comparing disease severity groups rather than 3 age, which is known to impact immune responses and is proportionately enriched in those weeks to months later whereas we were inferring the level of protection at the titres measured 16 at 12 months and hence we may have underestimated the level of protection.

The authors would like to thank the study participants for their contribution to the research, as Inclusion and diversity 16 We worked to ensure gender balance in the recruitment of human subjects. We worked to 17 ensure that the study questionnaires were prepared in an inclusive way. One or more of the 18 authors of this paper self-identifies as an underrepresented ethnic minority in science. One or 19 more of the authors of this paper self-identifies as a member of the LGBTQ+ community. 21 The authors declare no competing interests. March and April 2020 in Sydney, Australia, where local transmission was very low at the time.

None of these 9 healthy controls had a history of COVID-19, were not close contacts of cases of COVID-19 and were not health care workers. For the memory B cell assays stored PBMCs 1 from two of these healthy controls and stored PBMCs from four Australian Red Cross 2 Lifeblood donors collected prior to 2020 were used (median age 38, range 25 to 48). Cryopreserved PBMCs were thawed rapidly in a 37°C waterbath and washed with pre-warmed 10 RPMI media supplemented with 2mM L-glutamine, 50IU/mL penicillin, 50μg/mL 11 streptomycin and 10% heat inactivated fetal calf serum (Sigma were acquired for each sample. The data analysis was performed using FlowJo version 10.7.1 4 (TreeStar). The assay cut off was designated as mean + 2 SD calculated from 6 healthy controls.

Ex vivo phenotyping and T cell activation assay (AIM Assay) 6 Cryopreserved PBMCs were thawed using RPMI (+L-glut) medium (ThermoFisher One year after SARS-CoV-2 infection, despite declining antibody titers, Balachandran et al report a disease severity associated maintenance of antibody functions and memory B cell magnitude. The convalescent serum could neutralise most VOCs, and the initial CD4 T cell levels predict the antibody neutralisation breadth and memory B cell durability.

 SARS-CoV-2 specific humoral immunity is sustained at 12 months post-infection  Severe disease is associated with more durable immune responses  Immune responses are equivalent to a vaccine protective efficacy of 45-76%

 Early CD4 T cell responses predict durable neutralisation and memory B cells J o u r n a l P r e -p r o o f

Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain 13 among COVID-19 convalescent plasma donors in Wuhan

1.617 by vaccine and convalescent serum

1+CXCR3−CXCR5+ Memory Tfh Cells Are Highly Functional and Correlate with Broadly 20 Neutralizing HIV Antibody Responses

Circulating